Metal-dependent inhibition of HIV-1 integrase

Journal of Medicinal Chemistry

Volumn 45, Issue 26, 2002, Pages 5661-5670

  Neamati, Nouri ^a   Lin, Zhaiwei ^b   Karki, Rajeshri G ^b   Orr, Ann ^c   Cowansage, Kiriana ^a   Strumberg, Dirk ^c   Pais, Godwin C G ^b   Voigt, Johannes H ^b   Nicklaus, Marc C ^b   Winslow, Heather E ^c   Zhao, He ^b   Turpin, Jim A ^d   Yi, Jizu ^e   Skalka, Anna Marie ^e   Burke Jr , Terrence R ^c   Pommier, Yves ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); HYDRAZIDE DERIVATIVE; INTEGRASE; MERCAPTOSALICYLHYDRAZIDE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SALICYLHYDRAZIDE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CHELATION; COMPLEX FORMATION; CYTOTOXICITY; DNA PROTEIN COMPLEX; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; VIRUS ADSORPTION; VIRUS ASSEMBLY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BINDING SITES; CATALYTIC DOMAIN; CATIONS, DIVALENT; CELL LINE; CHELATING AGENTS; CYSTEINE; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; HYDRAZINES; MAGNESIUM; MANGANESE; MODELS, MOLECULAR; SALICYLIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

EID: 0037137602     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0201417     Document Type: Article

References (52)

1. Asante-Appiah, E.; Skalka, A. M. HIV-1 integrase: Structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
2. Hazuda, D. J.; Hastings, J. C.; Wolfe, A. L.; Emini, E. A. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res. 1994, 22, 1121-1122.
3. Mazumder, A.; Neamati, N.; Sunder, S.; Owen, J.; Pommier, Y. Retroviral integrase: A novel target in antiviral development; basic in vitro assays with the purified enzyme. In Methods in Cellular and Molecular Biology: Antiviral Evaluation; The Humana Press: Totowa, NJ, 1999.
4. Chow, S. A. In vitro assays for activities of retroviral integrase. Methods 1997, 12, 306-317.
5. Debyser, Z.; Cherepanov, P.; Pluymers, W.; De Clercq, E. Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol. Biol. 2001, 160, 139-155.
6. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. Drug Discovery Today 1997, 2, 487- 498.
7. Neamati, N.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: Past, present, and future. Adv. Pharmacol. 2000, 49, 147-165.
8. Neamati, N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Invest. Drugs 2001, 10, 281- 296.
9. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: A ten-year saga. Expert Opin. Ther. Pat. 2002, 12, 709-724.
10. Pommier, Y.; Neamati, N. Inhibitors of human immunodeficiency virus integrase. Adv. Virus Res. 1999, 52, 427-458.
11. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646- 650.
12. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. In Vitro Activity of a New HIV-1 Integrase Inhibitor in Clinical Development. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
13. Neamati, N.; Barchi, J. J., Jr. New paradigms in drug design and discovery. Curr. Top. Med. Chem. 2002, 2, 211-227.
14. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
15. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; et al. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
16. Neamati, N.; Hong, H.; Owen, J. M.; Sunder, S.; Winslow, H. E.; et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: Implication for a selective chelation in the integrase active site. J. Med. Chem. 1998, 41, 3202-3209.
17. Urpi, F.; Vilarrasa, J. New synthetic tricks. Advantages of using triethylphosphine in some phosphorous-based reactions. Tetrahedron Lett. 1986, 27, 4623-4624.
18. Maiti, S. N.; Spevak, P.; Singh, M. p.; Micetich, R. G.; Reddy, V. N. Reductive cleavage of symmetrical disulfides with hydrazine. Synth. Commun. 1988, 18, 575-582.
19. Houk, J.; Whitesides, G. M. Structure-activity relationships for thiol-disulfide interchanges. J. Am. Chem. Soc. 1987, 109, 6825-6836.
20. Cowan, J. A. The Biological Chemistry of Magnesium; VCH: New York, 1995; pp 1-23.
21. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; et al. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
22. Hazuda, D. J.; Felock, P. J.; Hastings, J. C.; Pramanik, B.; Wolfe, A. L. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J. Virol. 1997, 71, 7005-7011.
23. Mazumder, A.; Neamati, N.; Pilon, A. A.; Sunder, S.; Pommier, Y. Chemical trapping of ternary complexes of human immunodeficiency virus type 1 integrase, divalent metal, and DNA substrates containing an abasic site. Implications for the role of lysine 136 in DNA binding. J. Biol. Chem. 1996, 271, 27330-27338.
24. Ellison, V.; Brown, P. O. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7316-7320.
25. Careaga, C. L.; Falke, J. J. Thermal motions of surface alphahelices in the D-galactose chemosensory receptor. Detection by disulfide trapping. J. Mol. Biol. 1992, 226, 1219-1235.
26. Creighton, T. E. Disulfide bond formation in proteins. Methods Enzymol. 1984, 107, 305-329.
27. Pommier, Y.; Kohlhagen, G.; Kohn, K. W.; Leteurte, F.; Wani, M. C.; et al. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase 1-DNA cleavage sites. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8861-8865.
28. Neamati, N.; Mazumder, A.; Zhao, H.; Sunder, S.; Burke, T. R., Jr.; et al. Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother. 1997, 41, 385-393.
29. Neamati, N.; Mazumder, A.; Sunder, S.; Owen, J. M.; Schultz, R. J.; et al. 2-Mercaptobenzenesulfonamides as novel class of human immunodeficiency type 1 (HIV-1) integrase and HIV-1 replication. Antimicrob. Agents Chemother. 1997, 8, 485-495.
30. Lubkowski, J.; Yang, F.; Alexandratos, J.; Wlodawer, A.; Zhao, H.; et al. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4831-4836.
31. 2+ complexes of adenine nucleotides and thionucleotides and rate constants for formation and dissociation of MgATP and MgADP. Biochemistry 1984, 23, 5262-5271.
32. Sarnovsky, R. J.; May, E. W.; Craig, N. L. The Tn7 transposase is a heteromeric complex in which DNA breakage and joining activities are distributed between different gene products. EMBO J. 1996, 15, 6348-6361.
33. Clanton, D. J.; Buckheit, R. W.; Terpening, S. J.; Kiser, R.; Mongelli, N.; et al. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res. 1995, 27, 335-354.
34. Bader, J. P.; McMahon, J. B.; Schultz, R. J.; Narayanan, V. L.; Pierce, J. B.; et al. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6740-6744.
35. Kageyama, S.; Mimoto, T.; Murakawa, Y.; Nomizu, M.; Ford, H., Jr.; et al. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 1993, 37, 810-817.
36. Asante-Appiah, E.; Merkel, G.; Skalka, A. M. Purification of untagged retroviral integrases by immobilized metal ion affinity chromatography. Protein Expression Purif. 1998, 12, 105-110.
37. Yi, J.; Asante-Appiah, E.; Skalka, A. M. Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase. Biochemistry 1999, 38, 8458-8468.
38. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; et al. Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
39. Rice, W. G.; Supko, J. G.; Malspeis, L.; Buckheit, R. W. J.; Clanton, D.; et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1995, 270, 1194-1197.
40. Turpin, J. A.; Terpening, S. J.; Schaeffer, C. A.; Yu, G.; Glover, C. J.; et al. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J. Virol. 1996, 70, 6180-6189.
41. Rice, W. G.; Bader, J. P. Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. Adv. Pharm. 1995, 33, 389-438.
42. Rice, W. G.; Baker, D. C.; Schaeffer, C. A.; Graham, L.; Bu, M.; et al. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. 1997, 41, 419-426.
43. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; et al. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
44. Macromodel, version 7.0; Schrodinger Inc.: Portland, OR, 1999.
45. TITAN, version 1; Schrodinger Inc.: Portland, OR, 1999.
46. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Salvador, P.; Dannenberg, J. J.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian, Revision A.11; Gaussian, Inc.: Pittsburgh, PA, 2001.
47. Schrodinger, I. Glide/First Discovery 1.8; Schrodinger, Inc.: Portland, OR, 2001.
48. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
49. SYBYL, version 6.8; Tripos Inc.: St. Louis, MO, 2001.
50. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359-368.
51. InsightII; Accelrys: San Diego, CA. 1997.
52. Maple, J. R.; Dinur, U.; Hagler, A. T. Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354.